Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene®, a hepatitis B vaccine containing pre-S1, pre-S2 and S gene products

Vaccine

Volumn 16, Issue 6, 1998, Pages 543-550

  Pride, Michael W ^a,d   Bailey, Christopher R ^b   Muchmore, Elizabeth ^c   Thanavala, Yasmin ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Medeva Group Development   (United Kingdom)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d Wyeth Lederle Vaccines and Pediat ^*  (United States)

Author keywords

Hepatitis B surface antigens; In vitro cellular responses; In vivo humoral responses

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL LINE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; DRUG MANUFACTURE; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION;

ANIMALS; B-LYMPHOCYTES; EPITOPES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; LYMPHOCYTE ACTIVATION; PAN TROGLODYTES; PROTEIN PRECURSORS; T-LYMPHOCYTES;

EID: 0032053435     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00242-9     Document Type: Article

References (59)

1. 1 Sherlock, S., Diseases of the Liver and Biliary System, Blackwell Scientific Publications, London, 1981, 244 pp.
2. 2 DeGroute, J., Feuery, J. and Lepoutue, L. Long-term follow up of chronic active hepatitis of modest severity. Gut 1978, 19, 510-513.
3. 3 Beasley, R.P., Hwang, LY., Lin, C.C. and Chien, C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981, 2, 1129-1133.
4. 4 Obata, H., Hayashi, N. and Motoike, Y. A prospective study of development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection. Int. J. Cancer 1980, 25, 741-747.
5. 5 Szmuness, W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog. Med. Virol. 1978, 24, 40-69.
6. 6 Thomas, H.C., Montana, L., Goodall, A., DeKoning, R., Oladopo, J. and Wiedman, K.H. Immunological mechanisms in chronic hepatitis B virus infection. Hepatology 1982, 2, 116S-121S.
7. 7 Bayer, M.E., Blumberg, B.S. and Werner, B. Particles associated with Australia antigen in the sera of patients with leukemia, Downs Syndrome and hepatitis. Nature 1968, 218, 1057-1059.
8. 8 Dane, D.S., Cameron, C.H. and Briggs, M. Virus-like particles in serum of patients with Australia antigen associated hepatitis. Lancet 1970, 1, 695-698.
9. 9 Alper, C.A., Krunskall, M.S., Marcus-Bagley, D., Craven, D.E., Katz, A.J., Brink, S.J., Dienstag, J.L., Awdeh, Z. and Yunis, E.J. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 1989, 321, 708-712.
10. 10 Egea, E., Iglesias, A., Salazar, M., Morimoto, C., Krunskall, M.S., Awdeh, Z., Schlossmann, S.F., Alper, C.A. and Yunis, E.J. The cellular basis for lack of antibody response to hepatitis B vaccine. J. Exp. Med. 1991, 173, 531-538.
11. 11 Kruskall, M.S., Alper, C.A., Awdeh, Z., Yunis, E.J. and Marcus-Bagley, D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 1992, 175, 495-502.
12. - suppressor T-cells. Human Immunology 1988, 22, 9-17.
13. 13 Watanabe, H., Okumura, M., Hirayama, K. and Sasazuki, T. HLA-Bw64-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T-cells. Tissue Antigens 1990, 36, 69-74.
14. 14 Szmuness, W., Stevens, C.E., Harley, E.J., Zang, E.A., Olesiko, W.R., William, D.C., Sadovsky, R., Morrison, J.M. and Kellner, A. Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 1980, 303, 833-841.
15. 15 Stevens, C.E., Alter, H.J., Taylor, P.E., Zang, E.A., Harley, E.J., Szmuness, W. and the dialysis vaccine trial study group, Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N. Engl. J. Med., 1984, 311, 496-501.
16. 16 Degos, F., Duhamel, G., Brechot, C., Nalpas, B., Courouce, A.M., Tron, F. and Berthelot, P. Hepatitis B vaccination in chronic alcoholics. J. Hepatol. 1986, 2, 402-409.
17. 17 Milich, D.R. Genetic and molecular basis for T- and B-cell recognition of hepatitis B viral antigens, Immunol Rev. 1987, 99, 71-103.
18. 18 Stephenne, J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990, 8, S69-S73.
19. 19 Yap, I., Guan, R. and Chan, S.H. Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein - a preliminary study on immunoqenicity. Vaccine 1992, 10, 439-442.
20. 20 Cheng, K.C. and Moss, B. Selective synthesis and secretion of particles composed of the hepatitis B virus: induction of antibodies to pre-S and S epitopes. J. Virol. 1987, 61, 1286-1290.
21. 21 Cheng, K.C., Smith, G.L and Moss, B. Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus. J. Virol. 1986, 60, 337-344.
22. 22 Smith, G.L., Mackett, M. and Moss, B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 1983, 302, 490-495.
23. 23 Bhatnager, P.K., Papas, E., Blum, H.E., Milich, D.R., Nitecki, D., Karels, M.J. and Vyas, G.N. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc. Natl. Acad. Sci. USA 1982, 79, 4400-4404.
24. 24 Ionescu-Matiu, I., Kennedy, R.C., Sparrow, J.T., Culwell, A.R., Sanchez, Y., Melnick, J.L. and Dreesman, G.R. Epitopes associated with a synthetic hepatitis B surface antigen peptide. J. Immunol. 1983, 130, 1947-1952.
25. 25 Manivel, V., Tripathy, A., Durgapal, H., Kumar, A., Panda, S.K. and Rao, K.V.S. A self-associating hepatitis B surface antigen-derived peptide that is immunogenic in alum. Vaccine 1993, 11, 366-371.
26. 26 Lerner, R.A., Green, N., Alexander, H., Liu, F.T., Sutcliffe, J.G. and Shinnick, T.M. Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles, Proc. Natl. Acad. Sci. USA 1981, 78, 3403-3407.
27. 27 Kennedy, R.C., Eichberg, J.W., Lanford, R.E. and Dreesman, D.R. Anti-idiotypic antibody vaccine for type B viral hepatitis in chimpanzees. Science 1986, 232, 220-223.
28. 28 Pride, M.W., Shi, H., Anchin, J.M., Linthicum, D.S., LoVerde, PT., Thakur, A. and Thanavala, Y. Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc. Natl. Acad. Sci. USA 1992, 89, 11900-11904.
29. 29 Pride, M.W., Thakur, A. and Thanavala, Y. Mimicry of the a determinant of hepatitis B surface antigen by an antiidiotypic antibody. J. Exp. Med. 1993, 177, 127-134.
30. 30 Hemmerling, A.E., Muller, R., Firusian, N., Grötz, J., Haubitz, M. and Thoma, H.A. Clinical experience with the preS1-containing hepatitis B vaccine (HG-3) in different nonresponders groups. Viral Hepatitis and Liver Disease 1994, 87, 540-542.
31. 31 Neurath, A.R., Kent, S.B.H., Strick, N. and Parker, K. Identification and chemical synthesis of host-cell receptor binding site on hepatitis B virus. Cell 1986, 46, 429-436.
32. 32 Yoneyama, T., Akatsuka, T. and Miyamura, T. Stable expression of the hepatitis B virus surface antigen containing pre-S2 protein in mouse cells using a bovine papilloma virus vector. J. Gen. Virol. 1988, 69, 1931-1939.
33. 33 Samanta, H. and Youn, B.W. Expression of hepatitis B virus surface antigen containing the pre-S region in mammalian cell culture system. Vaccine 1989, 7, 69-76.
34. 34 Pavlakis, G.N. and Hamer, D.H. Regulation of a metallothionein-growth hormone hybrid gene in bovine papilloma virus. Proc. Natl. Acad. Sci. USA 1983, 80, 387-401.
35. 35 Neurath, A.R., Pride, M.W., Strick, N. and Thanavala, Y. Toleration of amino acid substitutions within hepatitis B virus envelope protein epitopes established by peptide replacement set analysis. I. Region S (139-147). Peptide Res. 1990, 3, 116-122.
36. 36 Thanavala, Y.M., Bond, A., Tedder, R., Hay, F.C. and Roitt, I.M. Monoclonal internal image' anti-idiotypic antibodies of hepatitis B surface antigen. Immunology 1985, 55, 197-204.
37. 37 Thanavala, Y.M., Bond, A., Hay, F.C. and Roitt, I.M. Immunofluorescent technique for the detection of monoclonal internal image anti-idiotype antibodies of hepatitis B surface antigen. J. Immunol. Methods 1985, 83, 227-232.
38. 38 British Medical Association, A code of practice for implementation of the UK hepatitis B immunization guidelines for the protection of patients and staff. BMA, London, 1994.
39. 39 Okamoto, H., Imai, M., Usuda, S., Tanaka, E., Tachibana, K., Mishiro, S., Machida, A., Nakamura, T., Miyakawa, Y. and Mayumi, M. Hemagglutination assay of polypeptide coded by the pre-S region of hepatitis B virus DNA with monoclonal antibody; correlation of pre-S polypeptide with the receptor for polymerized human serum albumin in serums containing hepatitis B antigens. J. Immunol. 1985, 134, 1212-1216.
40. 40 Machida, A., Kishimoto, S., Ohnuma, H., Miyamoto, H., Baba, K., Oda, K., Nakamura, T., Miyakawa, Y. and Mayumi, M. A hepatitis surface antigen polypeptide (p31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenferology 1983, 85, 268-274.
41. 41 Yu, M.W., Flnlayson, J.S. and Shih, J.W.-K. Interaction between various polymerized human albumins and hepatitis B surface antigen, J. Virol. 1985, 55, 736-743.
42. 42 Machida, A., Kishmota, S., Ohnuma, H., Baba, K., Ito, Y., Miyamoto, H., Funatsu, G., Oda, K., Usuda, S., Togami, S., Nakamura, T., Miyakawa, Y. and Mayumi, M. A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology 1984, 86, 910-918.
43. 43 Pontisso, P., Petit, M.-A., Bankowski, M.J. and Peeples, M.E. Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J. Virol. 1989, 63, 1981-1988.
44. 44 Emini, E.A., Larson, V., Eichberg, J., Conrad, P., Garsky, V.M., Lee, D.L., Ellis, R.W., Miller, W.J., Anderson, C.A. and Gerety, R.J. Protective effects of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein. J. Med. Virol. 1989, 28, 7-12.
45. 45 Itoh, Y., Takai, E., Ohnuma, H., Kitajima, K., Tsuda, F., Machida, A., Mishiro, S., Nakamura, T., Miyakawa, Y. and Mayumi, M. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: Protective efficacy in chimpanzees. Proc. Natl. Acad. Sci. USA 1986, 83, 9174-9178.
46. 46 Neurath, A.R., Kent, S.B.H., Parker, K., Prince, A.M., Strick, N., Brotman, B. and Sproul, P. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 1986, 4, 35-37.
47. 47 Thornton, G.B., Moriarty, A.M., Milich, D.R., Eichberg, J.W., Purcell, R.H. and Gerin, J.L., Protection of chimpanzees from hepatitis-B virus infection after immunization with synthetic peptides: identification of protective epitopes in the pre-S region. In Vaccines Eighty-Nine: Modern Approaches to New Vaccines including the Prevention of AIDS, ed. R.A. Lerner, Cold Spring Harbor, 1989, pp. 467-471.
48. 48 Milich, D.R., Thornton, G.B., Neurath, A.R., Kent, S.B.H., Michel, M.-L., Tiollais, P. and Chisari, F.V. Enhanced immunogenicity of the pre-S region of the hepatitis surface antigen. Science 1985, 228, 1195-1199.
49. 49 Milich, D.R., McLachlan, A., Chisari, F.V., Kent, S.B.H. and Thornton, G.B. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T-cell response can by pass nonresponsiveness to the pre-S(2) and S region of HBsAg. J. Immunol. 1986, 137, 315-322.
50. 50 Milich, D.R., McNamara, M.K., McLachlan, A., Thornton, G.B. and Chisari, F.V. Distinct H-2 linked regulation of T-cell responses to the pre-S and S region of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc. Natl. Acad. Sci. USA 1985, 82, 8168-8172.
51. 51 Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panel, A., Even-Chen, Z., Gorecki, M. and Gerlich, W.H. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994, 12, 1453-1459.
52. 52 Akahane, Y. Clinical trial of a pre-S2 containing recombinant hepatitis B vaccine. Viral Hepatitis and Liver Disease 1994, 87, 533-535.
53. 53 Suzuki, H., Iino, S., Shiraki, K., Akahane, Y., Okamoto, H., Domoto, K. and Mishiro, S. Safety and efficacy of a recombinant yeast-derived pre-S2+ S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine 1994, 12, 1090-1096.
54. 54 Wagner, D., Wagenbreth, I., Stachan-Kunstyr, R., Thoma, H.A., Hemmerling, A.E. and Flik, J. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products. Clin. Invest. 1994, 72, 350-352.
55. 55 Leroux-Roels, G., Van Hecke, E., Michielsen, W., Voet, P. and Pêtre, J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994, 12, 812-818.
56. 56 Schellekens, H., de Reus, A., Peetermans, J.H. and Van Eerd, P.A.C.M. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitits B surface antigen. Postgraduate Med. J. 1987, 63, (Suppl. 2), 93-96.
57. 57 Fujisawa, Y., Kuroda, S., Van Eerd, P.A.C.M., Schellekens, H. and Kakinuma, A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2+ S) protein particles (a third generation vaccine). Vaccine 1990, 8, 192-198.
58. 58 Whittle, H.C., Maine, N., Pilkington, J., Mendy, M., Fortuin, M., Bunn, J., Allison, L., Howard, C. and Hall, A. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995, 345, 1089-1092.
59. 59 Marchou, B., Picot, N., Chavanet, P., Auvergnat, J.C., Armengaud, M., Devilliers, P., Cerisier, J.E., Marié, F.N. and Excler, J.L. Three-week hepatitis B vaccination provides protective immunity. Vaccine 1993, 11, 1383-1385.